People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Renibus Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $180.1M | $1.7B | 2019 |
Bhupinder Jeffrey Singh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bhupinder Jeffrey Singh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dale Jones | 1 | 3 |
| Alvaro Guillem | 1 | 3 |
| Carlos Guillem | 1 | 1 |
| Harpreet Kaur | 1 | 1 |
| Jocelyn D. Keyser | 1 | 1 |
| Jamie Jeffrey Donadio | 1 | 1 |
| D. Jeffrey Keyser | 1 | 1 |
| Henrik Jeffrey Rasmussen | 1 | 1 |
| Frank Jeffrey Stonebanks | 1 | 1 |
| Nels D. Bergmark | 1 | 1 |
| Jennifer D. Rasmussen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.